Back to mobile site
Get it on Google Play

Biogen reports 52-week phase 2 data for lupus skin drug litifilimab

October 2, 2026 11:20 AM EDT Send to a Friend
Biogen Inc. (Nasdaq: BIIB) announced 52-week results from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 study evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login